What is Function Oncology?
Function Oncology is at the forefront of delivering differentiated insights into patients and diseases, aiming to enhance patient outcomes through advanced data analysis. The company's core innovation lies in its platform for CRISPR-powered personalized functional genomics. This technology enables efficient, scalable, and individualized assessment of target vulnerabilities directly within clinical samples, identifying therapeutic opportunities previously inaccessible. For future patients, this platform is instrumental in powering the development of novel therapies against critical disease drivers that may otherwise remain hidden.
How much funding has Function Oncology raised?
Function Oncology has raised a total of $28M across 1 funding round:
Series A
$28M
Series A (2023): $28M with participation from Section 32 and Casdin Capital
Key Investors in Function Oncology
Section 32
Section 32 is a venture capital firm focused on investing in cutting-edge technology, particularly within the life sciences sector. They back visionary entrepreneurs and emerging technologies, aiming to support companies at the forefront of innovation.
Casdin Capital
Casdin Capital is a venture capital firm with deep expertise in financing life science innovation, particularly in diagnostics and molecular information. They have a history of investing in leading companies in the genomics and personalized medicine space.
What's next for Function Oncology?
The recent major strategic investment positions Function Oncology for accelerated growth and further platform development. This capital infusion is expected to bolster the company's research and development efforts, potentially expanding its clinical applications and therapeutic pipeline. The focus on personalized functional genomics suggests a strategic push towards precision medicine, aiming to solidify its market position in the competitive oncology landscape.
See full Function Oncology company page
